Automate Your Wheel Strategy on SNY
With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNY
- Rev/Share 17.4767
- Book/Share 28.4784
- PB 1.4864
- Debt/Equity 0.3183
- CurrentRatio 1.2739
- ROIC 0.0666
- MktCap 103757214307.3104
- FreeCF/Share 0.8481
- PFCF 49.5734
- PE 11.4022
- Debt/Assets 0.1783
- DivYield 0.0453
- ROE 0.1239
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SNY | Morgan Stanley | Equal Weight | Overweight | -- | $58 | Sept. 8, 2025 |
| Upgrade | SNY | Deutsche Bank | Hold | Buy | -- | -- | Sept. 2, 2025 |
| Upgrade | SNY | JP Morgan | Neutral | Overweight | -- | -- | Aug. 8, 2025 |
| Initiation | SNY | Exane BNP Paribas | -- | Outperform | -- | $65 | April 15, 2025 |
| Initiation | SNY | Goldman | -- | Neutral | -- | $65 | March 21, 2025 |
| Upgrade | SNY | Deutsche Bank | Sell | Hold | -- | -- | Jan. 30, 2025 |
News
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.
Read More
Sanofi Expands Insulin Savings Program To Cover All US Patients
Published: September 26, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: SNY) Genzyme Corporation.
Read More
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Read More
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Read More
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
Read More
Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo at week 16 Dual-target Nanobody® VHH inhibiting TNF and OX40L being explored across a range of immune-mediated diseases Reaffirms Sanofi's commitment to addressing underlying inflammation across complex, heterogeneous chronic skin diseases Paris, September 17, 2025. New data from the HS-OBTAIN phase 2a study (clinical study identifier: NCT05849922) show that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical …
Read More
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
Read More
Sanofi market value tanks following weak results on eczema drug trials
Published: September 04, 2025 by: Fast Company
Sentiment: Negative
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab disappointed Wall Street.
Read More
Why Is Sanofi Stock Falling Thursday?
Published: September 04, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company's ability to sustain its dermatology franchise once patent protections expire.
Read More
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Read More
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
Published: September 04, 2025 by: Benzinga
Sentiment: Negative
French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company's ability to sustain its dermatology franchise once patent protections expire.
Read More
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Published: September 04, 2025 by: Investors Business Daily
Sentiment: Negative
Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.
Read More
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Read More
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Read More
Sanofi: Playing To Win
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Positive
Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongside a robust late-stage pipeline, underpin future revenue potential. Risks include heavy Dupixent reliance, looming patent expirations, US policy uncertainty, and ongoing legal disputes with Regeneron.
Read More
Press release: Online availability of Sanofi's half-year financial report for 2025
Published: July 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.
Read More
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
Read More
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myeloma Paris, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM).
Read More
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
Published: July 28, 2025 by: Reuters
Sentiment: Negative
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday.
Read More
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Read More
Thermo Fisher acquires Sanofi's New Jersey manufacturing site
Published: July 16, 2025 by: Reuters
Sentiment: Positive
Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
Read More
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
Read More
SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Published: June 20, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive t.
Read More
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
Read More
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
Published: June 18, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
Read More
About Sanofi (SNY)
- IPO Date 2002-07-01
- Website https://www.sanofi.com
- Industry Drug Manufacturers - General
- CEO Paul Hudson
- Employees 82878